Genentech - A Member of the Roche Group

/ Scientists Jagath  Reddy Junutula - Senior Scientist, Discovery Oncology

Jagath Reddy Junutula

Senior Scientist, Discovery Oncology

Postdoc mentor icon POSTDOC MENTOR
  • 11
    years at Genentech
  • 14
    publications (2010-12)

My group focuses on translational projects involving development of antibody-based cancer therapeutics. Targeted therapy using monoclonal antibodies (MAbs) has revolutionized our approach to cancer treatment as several MAbs recognizing antigens expressed on the surface of tumor cells already have provided remarkable clinical benefit in the treatment of some types of cancers, and many others are currently in clinical development.

However, antibodies against tumor-specific antigens often lack therapeutic activity, they alternatively can be covalently linked to cytotoxic drugs to produce Antibody drug conjugates (ADCs), a promising technology for specifically targeting cytotoxic agents to tumor cells. We have recently developed a THIOMAB (antibodies with engineered cysteine residues) platform to obtain ADCs with uniform stoichiometry (~2 drugs/antibody). We are currently investigating the use of engineered THIOMAB drug conjugates to improve ADC therapeutic index, linker stability and mechanism action.

  • My Focus
  • Publications Down arrow
  • Education Down arrow